[Management of ocular adverse events associated with antibody-drug conjugates in the treatment of solid tumors: a consensus statement from Chinese experts (2025 edition)] - PubMed
6 hours ago
- #Ocular Adverse Events
- #Antibody-Drug Conjugates
- #Solid Tumors
- Antibody-drug conjugates (ADCs) have shown significant progress in treating solid tumors like breast, ovarian, cervical, urothelial carcinoma, and non-small cell lung cancer.
- Ocular adverse events from ADCs, such as dry eye and keratoconjunctivitis, are gaining clinical attention due to their impact on quality of life and treatment adherence.
- Differences in ADC payloads, targets, and mechanisms contribute to corneal disorders, leading to visual disturbances and reduced treatment compliance.
- This Chinese expert consensus aims to enhance awareness of ADC-related ocular events, promote safe ADC use, and improve patient outcomes based on recent evidence and multidisciplinary experience.